Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Ann Surg Oncol. 2025 Feb 1. doi: 10.1245/s10434-024-16642-6. Online ahead of print. ABSTRACT BACKGROUND: Previous results from the KEYNOTE-716 trial demonstrated significantly improved recurrence-free survival …